Company

TRACT

(Tissue Regenerative Activated Cell Therapy)

is the only technology that provides safe and efficient directed cells within a day in every clinic while being both patient and clinician friendly.

BioGenCell was established since One out of Four people in the world dies from vascular diseases. Millions of them suffer and die every year as modern medicine has not yet found effective and long lasting treatment for these diseases.

BioGenCell’s disruptive safe and effective TRACT technology platform provides a comprehensive scalable and readily accessible solution for all aspects of cell therapy, supporting scalable, automated manufacturing from both fresh and bio-banked tissues. The TRACT enables rapid creation of easy-to-use treatments for a wide range of degenerative diseases using highly standardized therapies derived from adult stem and progenitor cells.

Cell therapies are in the forefront of a new era of treating life-threatening incurable diseases.   Cell therapies can target, cancer, immune disorders and regenerative diseases such as vascular diseases in which blood flow is partially or totally blocked causing tissue damage and malfunction. In fact, Vascular diseases, including heart diseases (CVD) and peripheral arterial diseases (PAD), cause 30% of total global deaths often called “the silent killer” as 70%–80% of patients are asymptomatic.

BioGenCell’s Cell therapy innovative solutions for degenerative diseases have an immense market potential since they can regenerate function of damaged tissues even after many years of suffering.

For this end it is even more important to develop personalized medicine solutions where each patient’s comfort is secured and patientis provided with unique therapy based on his or her own medical profile.

The company was founded first and foremost with the vision of developing safe, effective and long lasting treatment for vascular diseases that will be  accessible to all patients.

BioGenCell is a leading force in creating solutions that use adult stem and progenitor cells and culture components derived from the patient’s own blood to regenerate their damaged tissues. Among other benefits the uniqueness of the TRACT cellular combination enables it to target both the chronic inflammation and the damaged tissue thus, targeting a wide range of degenerative diseases, including heart failure, stroke, blindness, cancer and immunological diseases.

The novel idea behind BioGenCell was to combine immune cells, the most therapeutic powerful medical technologies know today, with stem cell therapies to create a novel treatment that will have the benefits of all the components.

The first product that BioGenCell has tested and plans to introduce to the market will treat Critical Limb Ischemia (CLI) a severe form of Peripheral Arterial Diseases typical of diabetic patients, smokers and elderly populations. Critical Limb Ischemia patients suffer from constant pain (also known as ‘Rest pain’), devastatingly low quality of life, comparable to terminally ill cancer patients and they have a high incidence of amputation, disability and death. Initial clinical results have already proven the concept behind the company’s technology platform and its greater efficiency in terms of cost and time-of-production in comparison to the competition.of-production in comparison to the competition.

TRACT (Tissue Regenerative Activated Cell Therapy) is the only technology that provides safe and efficient directed cells within a day in every clinic while being both patient and clinician friendly.

BioGenCell was established since One out of Four people in the world dies from vascular diseases. Millions of them suffer and die every year as modern medicine has not yet found effective and long lasting treatment for these diseases.

BioGenCell’s disruptive safe and effective TRACT technology platform provides a comprehensive scalable and readily accessible solution for all aspects of cell therapy, supporting scalable, automated manufacturing from both fresh and bio-banked tissues. The TRACT enables rapid creation of easy-to-use treatments for a wide range of degenerative diseases using highly standardized therapies derived from adult stem and progenitor cells.

Cell therapies are in the forefront of a new era of treating life-threatening incurable diseases.   Cell therapies can target, cancer, immune disorders and regenerative diseases such as vascular diseases in which blood flow is partially or totally blocked causing tissue damage and malfunction. In fact, Vascular diseases, including heart diseases (CVD) and peripheral arterial diseases (PAD), cause 30% of total global deaths often called “the silent killer” as 70%–80% of patients are asymptomatic.

BioGenCell’s Cell therapy innovative solutions for degenerative diseases have an immense market potential since they can regenerate function of damaged tissues even after many years of suffering.

For this end it is even more important to develop personalized medicine solutions where each patient’s comfort is secured and patientis provided with unique therapy based on his or her own medical profile.

The company was founded first and foremost with the vision of developing safe, effective and long lasting treatment for vascular diseases that will be  accessible to all patients.

BioGenCell is a leading force in creating solutions that use adult stem and progenitor cells and culture components derived from the patient’s own blood to regenerate their damaged tissues. Among other benefits the uniqueness of the TRACT cellular combination enables it to target both the chronic inflammation and the damaged tissue thus, targeting a wide range of degenerative diseases, including heart failure, stroke, blindness, cancer and immunological diseases.

The novel idea behind BioGenCell was to combine immune cells, the most therapeutic powerful medical technologies know today, with stem cell therapies to create a novel treatment that will have the benefits of all the components.

The first product that BioGenCell has tested and plans to introduce to the market will treat Critical Limb Ischemia (CLI) a severe form of Peripheral Arterial Diseases typical of diabetic patients, smokers and elderly populations. Critical Limb Ischemia patients suffer from constant pain (also known as ‘Rest pain’), devastatingly low quality of life, comparable to terminally ill cancer patients and they have a high incidence of amputation, disability and death. Initial clinical results have already proven the concept behind the company’s technology platform and its greater efficiency in terms of cost and time-of-production in comparison to the competition.of-production in comparison to the competition.

Skip to content